Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
27 March 2017
E-002080-17
Question for written answer
to the Commission
Rule 130
Davor Škrlec (Verts/ALE)

 Subject:  Preventing and reducing pharmaceutical waste in freshwater
 Answer(s) 

Following the Water Framework Directive, some progress has been noted in the way in which Member States are monitoring and reporting on the proportions of certain substances in water, e.g. phosphorus and nitrogen. A more recent problem, however, is the release of pharmaceutical waste residues into freshwater.

The impact of pharmaceutical waste on health and the aquatic environment has not yet been fully investigated, and there is insufficient information on its concentration in European waters and sediment. Widely used drugs, such as analgesics, hormone medicines and antibiotics, have an adverse effect on aquatic life and thus ultimately on entire ecosystems.

Is the Commission planning to take specific measures to prevent the release of pharmaceutical waste into freshwater, as well as more concrete measures to monitor its concentration and quantify it at EU level? If so, how does it plan to implement these measures?

Original language of question: HR 
Last updated: 25 April 2017Legal notice